Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cellectis S.A. ADR
(NQ:
CLLS
)
2.860
-0.110 (-3.70%)
Streaming Delayed Price
Updated: 11:35 AM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cellectis S.A. ADR
< Previous
1
2
Next >
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
April 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
April 24, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
April 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
April 11, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
April 04, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
March 14, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 08, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
March 06, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
March 01, 2023
From
Cellectis Inc.
Via
GlobeNewswire
There's a Lot of Upside For Emerging Gene-Editing Companies
February 21, 2023
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.
Via
MarketBeat
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
February 07, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
February 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Pricing of Follow-On Offering
February 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Launch of Follow-On Offering
February 02, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
January 20, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
January 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
December 29, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
December 28, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
December 22, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
December 13, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
December 01, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
November 10, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
November 10, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
November 03, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
November 03, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report Third Quarter 2022 Financial Results
October 27, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
October 11, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05, 2022
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
September 28, 2022
From
Cellectis Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.